THE INFLUENCE OF AWARENESS OF PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS ABOUT THE MAGNITUDE OF THE FRAX 10-YEAR ABSOLUTE RISK OF FRACTURE ON THE DECISION TO START AND THE ADHERENCE TO ANTIOSTEOPOROTIC TREATMENT (INTERIM RESULTS OF «CRYSTAL» STUDY) | Zendy

O. M. Lesnyak | Zendy; Е. Н. Хосева | Zendy; L. V. Menshikova | Zendy; Т. В. Антонова | Zendy; И. М. Ивыгина | Zendy; E. Kapustina | Zendy; I I Veytsman | Zendy; И Б Белоусова | Zendy; Е. И. Ситникова | Zendy; S. Yu. Shkireeva | Zendy; О. Б. Божко | Zendy; Natalya Bezlyudnaya | Zendy; L Kh Gilyazeva | Zendy; N Yu Kozhevnikova | Zendy; Yu. V. Titova | Zendy; Е. Н. Чикина | Zendy; Н. Н. Калинина | Zendy; Irina E. Prokhorova | Zendy

Open Access

THE INFLUENCE OF AWARENESS OF PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS ABOUT THE MAGNITUDE OF THE FRAX 10-YEAR ABSOLUTE RISK OF FRACTURE ON THE DECISION TO START AND THE ADHERENCE TO ANTIOSTEOPOROTIC TREATMENT (INTERIM RESULTS OF «CRYSTAL» STUDY)

Author(s) -

O. M. Lesnyak,

Е. Н. Хосева,

L. V. Menshikova,

Т. В. Антонова,

И. М. Ивыгина,

E. Kapustina,

I I Veytsman,

И Б Белоусова,

Е. И. Ситникова,

S. Yu. Shkireeva,

О. Б. Божко,

Natalya Bezlyudnaya,

L Kh Gilyazeva,

N Yu Kozhevnikova,

Yu. V. Titova,

Е. Н. Чикина,

Н. Н. Калинина,

Irina E. Prokhorova

Publication year - 2014

Publication title -

osteoporosis and bone diseases

Language(s) - English

Resource type - Journals

eISSN - 2311-0716

pISSN - 2072-2680

DOI - 10.14341/osteo201427-10

Subject(s) - frax , medicine , osteoporosis , absolute risk reduction , adverse effect , randomized controlled trial , physical therapy , osteoporotic fracture , bone mineral , confidence interval

To assess the influence of informing patients with postmenopausal osteoporosis about the their probability of 10-year absolute fracture risk calculated by FRAX tool on the patient ’s decision to start treatment and their adherence to therapy during 3 years of follow-up. Materials and Methods. Multicenter open randomized trial included 417 women (mean age 65.9 years). Patients of the 1 group (n=191) were informed about the value of their absolute risk of fracture by FRAX. Patients of the 2 group (the control; n=196) got usual advice and recommendations without calculating FRAX. All patients were recommended to take alendronate in a standard dose (70 mg a week) and calcium/vitamin D supplements. Results. During the first three months after initial visit 96.4% of patients started their treatment. The adherence to treatment at sixth month was 7% higher in the group 1; the compliance in the group 1 was 8% higher, than in the control group. 6.4% of patients developed adverse drug reactions, which led to cancellation of therapy in only 2.9% of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research